Therapeutic approaches to chronic intestinal inflammation by specific targeting of mucosal IL-7/IL-7R signal pathway

Curr Drug Targets Inflamm Allergy. 2003 Jun;2(2):119-23. doi: 10.2174/1568010033484269.

Abstract

Inflammatory bowel disease is thought to result from inappropriate activation of mucosal immune responses. Intestinal epithelial cells produce interleukin (IL)-7 that serves as a regulatory factor for IL-7 receptor (IL-7R)(+) mucosal lymphocytes. The pivotal role of mucosal IL-7/IL-7R dependent signals in the activation of mucosal immune responses that lead to the development of chronic intestinal inflammation are demonstrated. Therapeutic approaches targeting IL-7/IL-7R signal pathway may be feasible in the treatment of inflammatory bowel disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Chronic Disease
  • Drug Delivery Systems
  • Humans
  • Interleukin-7 / immunology
  • Interleukin-7 / physiology*
  • Intestinal Diseases / drug therapy*
  • Intestinal Diseases / immunology
  • Intestinal Diseases / physiopathology
  • Intestinal Mucosa / pathology
  • Intestinal Mucosa / physiopathology
  • Lymphoid Tissue / physiopathology
  • Receptors, Interleukin-7 / drug effects
  • Receptors, Interleukin-7 / immunology
  • Receptors, Interleukin-7 / physiology*
  • Signal Transduction / drug effects
  • Signal Transduction / immunology
  • Signal Transduction / physiology*

Substances

  • Interleukin-7
  • Receptors, Interleukin-7